Nanomedizin in der HNO-Heilkunde – ein Ausblick

 

 Buy Article Permissions and Reprints

Zusammenfassung

Hintergrund:

Die Nanotechnologie gewinnt in der heutigen Welt zunehmend an Bedeutung. In der Medizin im Allgemeinen und speziell in der Hals-Nasen-Ohrenheilkunde verhält es sich ebenso. Im Wesentlichen lassen sich die folgenden Bereiche unterscheiden: Diagnostik, neue Therapien und Wirkstoffe, Wirkstofftransport („drug delivery“) und medizinische Implantate.

Material und Methoden:

Es erfolgte eine umfangreiche Literaturrecherche in den Datenbanken „PubMed/Medline“ und „Web of Science“ zur Nanomedizin in der Hals-Nasen-Ohrenheilkunde. Darüber hinaus wird ein aktueller Überblick über die Arbeiten der an der Hals-Nasen-OhrenKlinik, Kopf- und Halschirurgie des Universitätsklinikums Erlangen angesiedelten Sektion für Experimentelle Onkologie und Nanomedizin (SEON) gegeben.

Ergebnisse:

Zahlreiche neue und innovative Arbeiten zur Nanotechnologie in Diagnostik und Therapie konnten gefunden werden. Aufgrund der großen Vielfalt in der Hals-Nasen-Ohrenheilkunde gibt es hier, je nach Teilgebiet, die unterschiedlichsten Ansätze. Der Hauptanteil umfasst Arbeiten zum Wirkstofftransport.

Schlussfolgerungen:

Die Bemühungen, das Potenzial der Nanotechnologie in der Hals-Nasen-Ohrenheilkunde zu nützen, sind vielfältig und zukunftsträchtig. Die größte Aussicht auf Erfolg wird dabei den nanopartikulären Drug-Delivery-Systemen zugeschrieben.

Abstract

Nanomedicine in Otorhinolaryngology – Future Prospects

Background:

Nanotechnology becomes more and more important in the world of today. Equally, it does generally in medicine and of course specifically in otorhinolaryngology. Essentially, there are the following fields: Diagnostics, new therapies and agents, drug delivery and medical implants.

Material and Methods:

An extensive literature research on nanomedicine in otorhinolaryngology was carried out in the standard online medical reference databases “PubMed/Medline” and “Web of Science”. Furthermore, we are giving an overview of the work of the Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen.

Results:

A lot of new and innovative studies on nanotechnology in diagnostics and therapy were recovered. Depending on the variety in otorhinolaryngology, there are numerous versatile approaches, according to the different areas. The main part is engaged in drug delivery.

Conclusions:

The efforts to exploit the potential of nanotechnology in otorhinolaryngology are multifaceted, innovative and seminal. The best perspective of success is attributed to nanoparticulate drug delivery systems.

• Literatur

• 1 Feynman RP. There‘s plenty of room at the bottom. 1959 http://www.zyvex.com/nanotech/feynman.html
  PubMedGoogle Scholar
• 2 Taniguchi N. On the basic concept of nanotechnology. In: Proc Intl Conf Prod Eng Part II. Tokyo: Japan Society of Precision Engineering; 1974: 5-10
  Google Scholar
• 3 Krug HF, Wick P. Nanotoxikologie – eine interdisziplinäre Herausforderung. Angew Chem 2011; 123: 1294-1314
  CrossrefPubMedGoogle Scholar
• 4 Philpott CM, Gane S, McKiernan D. Nanomedicine in otorhinolaryngology: what does the future hold?. Eur Arch Otorhinolaryngol 2011; 268: 489-496
  CrossrefPubMedGoogle Scholar
• 5 Bawa R, Bawa SR, Maebius SB, Flynn T, Wei C. Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 2005; 1: 150-158
  PubMedGoogle Scholar
• 6 Wagner V, Wechsler D. Nanobiotechnologie II: Anwendungen in der Medizin und Pharmazie. Düsseldorf: VDI Technologiezentrum GmbH. ; 2004
  PubMedGoogle Scholar
• 7 OECD/Allianz Group. Small sizes that matter: Opportunities and Risks of Nanotechnologies 2005;
  PubMed
• 8 Praetorius M, Brunner C, Lehnert B, Klingmann C, Schmidt H, Staecker H, Schick B. Transsynaptic delivery of nanoparticles to the central auditory nervous system. Acta Otolaryngol 2007; 127: 486-490
  CrossrefPubMedGoogle Scholar
• 9 Thaler M, Roy S, Fornara A, Bitsche M, Qin J, Muhammed M, Salvenmoser W, Rieger G, Fischer AS, Glueckert R. Visualization and analysis of superparamagnetic iron oxide nanoparticles in the inner ear by light microscopy and energy filtered TEM. Nanomedicine 2011; 7: 360-369
  CrossrefPubMedGoogle Scholar
• 10 Roy S, Johnston AH, Newman TA, Glueckert R, Dudas J, Bitsche M, Corbacella E, Rieger G, Martini A, Schrott-Fischer A. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: Potential tool for drug delivery. Int J Pharm 2010; 390: 214-224
  CrossrefPubMedGoogle Scholar
• 11 Scheper V, Wolf M, Scholl M, Kadlecova Z, Perrier T, Klok HA, Saulnier P, Lenarz T, Stöver T. Potential novel drug carriers for inner ear treatment: hyperbranched polylysine and lipid nanocapsules. Nanomedicine (Lond) 2009; 4: 623-635
  CrossrefPubMedGoogle Scholar
• 12 Chen G, Zhang X, Yang F, Mu L. Disposition of nanoparticle-based delivery system via inner ear administration. Curr Drug Metab 2010; 11: 886-897
  CrossrefPubMedGoogle Scholar
• 13 Zhang W, Zhang Y, Löbler M, Schmitz KP, Ahmad A, Pyykkö I, Zou J. Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells. Int J Nanomedicine 2011; 6: 535-546
  PubMedGoogle Scholar
• 14 Mondalek FG, Zhang YY, Kropp B, Kopke RD, Ge X, Jackson RL, Dormer KJ. The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field. J Nanobiotechnology 2006; 4: 4
  CrossrefPubMedGoogle Scholar
• 15 Shapiro B, Dormer K, Rutel IB. A Two-Magnet System to Push Therapeutic Nanoparticles. AIP Conf Proc 2010; 1311: 77-88
  PubMedGoogle Scholar
• 16 Zou J, Sood R, Ranjan S, Poe D, Ramadan UA, Kinnunen PK, Pyykkö I. Manufacturing and in vivo inner ear visualization of MRI traceable liposome nanoparticles encapsulating gadolinium. J Nanobiotechnology 2010; 8: 32
  CrossrefPubMedGoogle Scholar
• 17 Stöver T, Lenarz T. Biomaterials in cochlear implants. Laryngo-Rhino-Otol 2009; 88: S12-S31
  PubMedGoogle Scholar
• 18 Nair LS, Laurencin CT. Nanofibers and nanoparticles for orthopaedic surgery applications. J Bone Joint Surg Am 2008; 90: 128-131
  CrossrefPubMedGoogle Scholar
• 19 Dormer K, Seeney C, Lewelling K, Lian G, Gibson D, Johnson M. Epithelial internalization of superparamagnetic nanoparticles and response to external magnetic field. Biomaterials 2005; 26: 2061-2072
  CrossrefPubMedGoogle Scholar
• 20 Kopke RD, Wassel RA, Mondalek F, Grady B, Chen K, Liu J, Gibson D, Dormer KJ. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol Neurootol 2006; 11: 123-133
  PubMedGoogle Scholar
• 21 Srinivas A, Rao PJ, Selvam G, Murthy PB, Reddy PN. Acute inhalation toxicity of cerium oxide nanoparticles in rats. Toxicol Lett 2011; 205: 105-115
  CrossrefPubMedGoogle Scholar
• 22 Hackenberg S, Friehs G, Froelich K, Ginzkey C, Koehler C, Scherzed A, Burghartz M, Hagen R, Kleinsasser N. Intracellular distribution, geno- and cytotoxic effects of nanosized titanium dioxide particles in the anatase crystal phase on human nasal mucosa cells. Toxicol Lett 2010; 195: 9-14
  CrossrefPubMedGoogle Scholar
• 23 Hackenberg S, Scherzed A, Technau A, Kessler M, Froelich K, Ginzkey C, Koehler C, Burghartz M, Hagen R, Kleinsasser N. Cytotoxic, genotoxic and pro-inflammatory effects of zinc oxide nanoparticles in human nasal mucosa cells in vitro. Toxicol In Vitro 2011; 25: 657-663
  CrossrefPubMedGoogle Scholar
• 24 Bilberg K, Døving KB, Beedholm K, Baatrup E. Silver nanoparticles disrupt olfaction in Crucian carp (Carassius carassius) and Eurasian perch (Perca fluviatilis). Aquat Toxicol 2011; 104: 145-152
  CrossrefPubMedGoogle Scholar
• 25 Griesenbach U, Geddes DM, Alton EW. Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 2004; 10: 542-546
  CrossrefPubMedGoogle Scholar
• 26 Lai SK, Suk JS, Pace A, Wang YY, Yang M, Mert O, Chen J, Kim J, Hanes J. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials 2011; 32: 6285-6290
  PubMedGoogle Scholar
• 27 Ellis-Behnke RG, Liang YX, Tay DK, Kau PW, Schneider GE, Zhang S, Wu W, So KF. Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2006; 2: 115-207
  PubMedGoogle Scholar
• 28 Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J, Oberdörster G. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006; 114: 1172-1178
  CrossrefPubMedGoogle Scholar
• 29 Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379: 146-157
  CrossrefPubMedGoogle Scholar
• 30 Patel S, Chavhan S, Soni H, Babbar AK, Mathur R, Mishra AK, Sawant K. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011; 19: 468-474
  CrossrefPubMedGoogle Scholar
• 31 Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 2009; 6: 359-371
  CrossrefPubMedGoogle Scholar
• 32 Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X. Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae. Clin Vaccine Immunol 2011; 18: 75-81
  CrossrefPubMedGoogle Scholar
• 33 Miranda OR, Creran B, Rotello VM. Array-based sensing with nanoparticles: “chemical noses” for sensing biomolecules and cell surfaces. Curr Opin Chem Biol 2010; 14: 728-736
  CrossrefPubMedGoogle Scholar
• 34 Allaker RP. The use of nanoparticles to control oral biofilm formation. J Dent Res 2010; 89: 1175-1186
  CrossrefPubMedGoogle Scholar
• 35 McCarron PA, Donnelly RF, Canning PE, McGovern JG, Jones DS. Bioadhesive, non-drug-loaded nanoparticles as modulators of candidal adherence to buccal epithelial cells: a potentially novel prophylaxis for candidosis. Biomaterials 2004; 25: 2399-2407
  CrossrefPubMedGoogle Scholar
• 36 Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul 2008; 2: 258-274
  CrossrefPubMedGoogle Scholar
• 37 Venugopalan P, Sapre A, Venkatesan N, Vyas SP. Pelleted bioadhesive polymeric nanoparticles for buccal delivery of insulin: preparation and characterization. Pharmazie 2001; 56: 217-219
  PubMedGoogle Scholar
• 38 Kolachala VL, Henriquez OA, Shams S, Golub JS, Kim YT, Laroui H, Torres-Gonzalez E, Brigham KL, Rojas M, Bellamkonda RV, Johns MM. Slow-release nanoparticle-encapsulated delivery system for laryngeal injection. Laryngoscope 2010; 120: 988-994
  PubMedGoogle Scholar
• 39 Xi J, Longest PW, Martonen TB. Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. J Appl Physiol 2008; 104: 1761-1777
  CrossrefPubMedGoogle Scholar
• 40 Henning A, Schneider M, Nafee N, Muijs L, Rytting E, Wang X, Kissel T, Grafahrend D, Klee D, Lehr CM. Influence of particle size and material properties on mucociliary clearance from the airways. J Aerosol Med Pulm Drug Deliv 2010; 23: 233-241
  CrossrefPubMedGoogle Scholar
• 41 Nauts HC, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand 1953; 276: 1-103
  PubMedGoogle Scholar
• 42 Johannsen M, Thiesen B, Wust P, Jordan A. Magnetic nanoparticle hyperthermia for prostate cancer. Int J Hyperthermia 2010; 26: 790-795
  CrossrefPubMedGoogle Scholar
• 43 Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011; 103: 317-324
  CrossrefPubMedGoogle Scholar
• 44 Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial. J Cancer Res Ther 2010; 6: 492-496
  CrossrefPubMedGoogle Scholar
• 45 Schmidtner J, Distel LV, Ott OJ, Nkenke E, Sprung CN, Fietkau R, Lubgan D. Hyperthermia and irradiation of head and neck squamous cancer cells causes migratory profile changes of tumour infiltrating lymphocytes. Int J Hyperthermia 2009; 25: 347-354
  CrossrefPubMedGoogle Scholar
• 46 Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef-Ezra JA, Smilowitz HM. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol 2010; 55: 3045-3059
  CrossrefPubMedGoogle Scholar
• 47 Damascelli B, Patelli G, Tichá V, Di Tolla G, Frigerio LF, Garbagnati F, Lanocita R, Marchianò A, Spreafico C, Mattavelli F, Bruno A, Zunino F. Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol 2007; 18: 1395-1403
  CrossrefPubMedGoogle Scholar
• 48 French JT, Goins B, Saenz M, Li S, Garcia-Rojas X, Phillips WT, Otto RA, Bao A. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol 2010; 21: 1271-1279
  CrossrefPubMedGoogle Scholar
• 49 El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 2006; 239: 129-135
  CrossrefPubMedGoogle Scholar
• 50 Pankhurst QA, Thanh NKT, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2009; 42: 224001-224016
  CrossrefPubMedGoogle Scholar
• 51 Gao Y. Biofunctionalization of magnetic nanoparticles. In: Kumar C (Hrsg) Biofunctionalization of nanomaterials. Weinheim: Wiley-VCH; 2005: 72-98 :
  Google Scholar
• 52 Duerr S, Lyer S, Mann J, Janko C, Herrmann M, Tietze R, Schreiber E, Alexiou C. Real-Time Cell Analysis (RTCA) of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res 2011; 31: 1966-1967
  PubMedGoogle Scholar
• 53 Alexiou C, Jurgons R, Seliger C, Iro H. Medical applications of magnetic nanoparticles. J Nanosci Nanotechnol 2006; 6: 2762-2768
  CrossrefPubMedGoogle Scholar
• 54 Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, Nativ O. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005; 16: 585-589
  CrossrefPubMedGoogle Scholar
• 55 Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliver Rev 1995; 17: 31-48
  CrossrefPubMedGoogle Scholar
• 56 Alexiou C, Tietze R, Schreiber E, Lyer S. Nanomedicine: Magnetic nanoparticles for drug delivery and hyperthermia – new chances for cancer therapy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53: 839-845
  PubMedGoogle Scholar
• 57 Alexiou C, Diehl D, Henninger P, Iro H, Rockelein R, Schmidt W, Weber H. A high field gradient magnet for magnetic drug targeting. IEEE Trans Appl Supercond 2006; 16: 1527-1530
  CrossrefPubMedGoogle Scholar
• 58 Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F. Magnetic drug targeting – biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 2003; 11: 139-149
  CrossrefPubMedGoogle Scholar
• 59 Tietze R, Rahn H, Lyer S, Schreiber E, Mann J, Odenbach S, Alexiou C. Visualization of superparamagnetic nanoparticles in vascular tissue using XμCT and histology. Histochem Cell Biol 2011; 135: 153-158
  CrossrefPubMedGoogle Scholar
• 60 Seliger C, Jurgons R, Wiekhorst F, Eberbeck D, Trahms L, Iro H, Alexiou C. In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J Magn Magn Mater 2007; 311: 358-362
  CrossrefPubMedGoogle Scholar
• 61 Alexiou C, Jurgons R, Schmid R, Erhardt W, Parak F, Bergemann C, Iro H. Magnetic Drug Targeting – a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies. HNO 2005; 53: 618-622
  CrossrefPubMedGoogle Scholar
• 62 Alexiou C, Arnold W, Hulin P, Klein RJ, Renz H, Parak FG, Bergemann C, Lübbe AS. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J Magn Magn Mater 2001; 225: 187-193
  CrossrefPubMedGoogle Scholar
• 63 Rahn H, Gomez-Morilla I, Jurgons R, Alexiou Ch, Odenbach S. Microcomputed tomography analysis of ferrofluids used for cancer treatment. J Phys Condens Matter 2008; 20: 204152-204156
  CrossrefPubMedGoogle Scholar
• 64 Alexiou C, Schmidt A, Klein RJ, Hulin P, Bergemann C, Arnold W. Magnetic drug targeting: biodistribution and dependency on magnetic field strength. J Magn Magn Mater 2002; 252: 363-366
  CrossrefPubMedGoogle Scholar
• 65 Lyer S, Tietze R, Jurgons R, Struffert T, Engelhorn T, Schreiber E, Dörfler A, Alexiou C. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles – a pilot study. Anticancer Res 2010; 30: 1553-1557
  PubMedGoogle Scholar
• 66 Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000; 60: 6641-6648
  PubMedGoogle Scholar
• 67 WHO Cancer. Fact sheet N°297, 2011. http://www.who.int/mediacentre/factsheets/fs297/en/index.html
  PubMed
• 68 Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981–2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005; 331: 614
  CrossrefPubMedGoogle Scholar
• 69 Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499
  CrossrefPubMedGoogle Scholar